PLURI INC
PLURNASDAQTrading Snapshot
- Day Range
- $1.01 β $1.01
- 52-Week Range
- $0.85 β $4.12
- Volume (shares)
- 1,037
- Avg Volume (shares)
- β
- Shares Outstanding
- 12.3M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $335,000
- P/E Ratio
- β
- P/S Ratio
- 99.6x
- EPS (TTM)
- $-2.46
- Dividend Yield
- β
- Dilution (1yr)
- +16.9%
PLURI INC
PLURAbout PLURI INC
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.